OBJECTIVE: To compare disease-specific survival (DSS) between the US and Korea following R0 resection for gastric carcinoma (GC). SUMMARY BACKGROUND DATA: Many studies have described decreased 5-year survival after curative gastrectomy for GC in the West compared with the East. Although clinicopathological presentations of GC are known to vary widely between Eastern and Western countries, including histology, tumor location, and stage at presentation, it remains unclear whether these factors account for differences in survival. METHODS: All patients undergoing curative intent resections (R0) for GC (1995-2005) were evaluated in 2 independent, single-institution prospectively maintained databases from the US (711 patients) and Korea (1646 patients). Patients receiving neoadjuvant chemotherapy were excluded from this analysis. Patient, surgical and pathologic variables were compared. DSS was determined via multivariate analysis using prognostic variables from an internationally validated GC nomogram that estimates the probability of 5- and 9-year survival. RESULTS: Age and body mass index were significantly higher in US patients. Location of tumors was more often proximal in the United States (39% vs. 9%, P < 0.0001) and distal in Korea (54% vs. 33%, P < 0.0001). Korean patients had more early stage tumors (42% vs. 28% stage Ia, P < 0.0001) with a higher number of lymph nodes identified (97% vs. 79%, >or=15 lymph nodes, P < 0.0001). The 5-year DSS was higher in Korea than in the United States. After multivariate analysis, applying factors used in the nomogram, DSS of Korean GC patients remained significantly better than that of US patients (HR = 1.3, 95% CI; 1.0-1.6, P = 0.008). CONCLUSIONS: This study demonstrates better survival for GC patients in Korea compared with the US as determined by multivariate analysis with a validated gastric cancer nomogram. Multiple possibilities can explain this difference.
OBJECTIVE: To compare disease-specific survival (DSS) between the US and Korea following R0 resection for gastric carcinoma (GC). SUMMARY BACKGROUND DATA: Many studies have described decreased 5-year survival after curative gastrectomy for GC in the West compared with the East. Although clinicopathological presentations of GC are known to vary widely between Eastern and Western countries, including histology, tumor location, and stage at presentation, it remains unclear whether these factors account for differences in survival. METHODS: All patients undergoing curative intent resections (R0) for GC (1995-2005) were evaluated in 2 independent, single-institution prospectively maintained databases from the US (711 patients) and Korea (1646 patients). Patients receiving neoadjuvant chemotherapy were excluded from this analysis. Patient, surgical and pathologic variables were compared. DSS was determined via multivariate analysis using prognostic variables from an internationally validated GC nomogram that estimates the probability of 5- and 9-year survival. RESULTS: Age and body mass index were significantly higher in US patients. Location of tumors was more often proximal in the United States (39% vs. 9%, P < 0.0001) and distal in Korea (54% vs. 33%, P < 0.0001). Korean patients had more early stage tumors (42% vs. 28% stage Ia, P < 0.0001) with a higher number of lymph nodes identified (97% vs. 79%, >or=15 lymph nodes, P < 0.0001). The 5-year DSS was higher in Korea than in the United States. After multivariate analysis, applying factors used in the nomogram, DSS of Korean GC patients remained significantly better than that of US patients (HR = 1.3, 95% CI; 1.0-1.6, P = 0.008). CONCLUSIONS: This study demonstrates better survival for GC patients in Korea compared with the US as determined by multivariate analysis with a validated gastric cancer nomogram. Multiple possibilities can explain this difference.
Authors: Kyung Jai Ko; Jung Ho Shim; Han Mo Yoo; Seong Il O; Hae Myung Jeon; Cho Hyun Park; Dong Jin Jeon; Kyo Young Song Journal: World J Surg Date: 2012-08 Impact factor: 3.352
Authors: Juan C Rodríguez-Sanjuán; Marcos Gómez-Ruiz; Soledad Trugeda-Carrera; Carlos Manuel-Palazuelos; Antonio López-Useros; Manuel Gómez-Fleitas Journal: World J Gastroenterol Date: 2016-02-14 Impact factor: 5.742
Authors: Stefano Caruso; Alberto Patriti; Franco Roviello; Lorenzo De Franco; Franco Franceschini; Andrea Coratti; Graziano Ceccarelli Journal: World J Gastroenterol Date: 2016-07-07 Impact factor: 5.742
Authors: Johan L Dikken; Cornelis J H van de Velde; Daniel G Coit; Manish A Shah; Marcel Verheij; Annemieke Cats Journal: Therap Adv Gastroenterol Date: 2012-01 Impact factor: 4.409
Authors: Manish A Shah; Minaxi Jhawer; David H Ilson; Robert A Lefkowitz; Edric Robinson; Marinela Capanu; David P Kelsen Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Elke J A H van Beek; Jonathan M Hernandez; Debra A Goldman; Jeremy L Davis; Kaitlin McLaughlin; R Taylor Ripley; Teresa S Kim; Laura H Tang; Jaclyn F Hechtman; Jian Zheng; Marinela Capanu; Nikolaus Schultz; David M Hyman; Marc Ladanyi; Michael F Berger; David B Solit; Yelena Y Janjigian; Vivian E Strong Journal: Ann Surg Oncol Date: 2018-05-03 Impact factor: 5.344
Authors: Takanobu Yamada; Takaki Yoshikawa; Masataka Taguri; Tsutomu Hayashi; Toru Aoyama; Henry M Sue-Ling; Kiran Bonam; Jeremy D Hayden; Heike I Grabsch Journal: Gastric Cancer Date: 2015-03-12 Impact factor: 7.370